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To better understand underlying causes of lower rotavirus vaccine effectiveness in low-middle income countries (LMICs), we meas-
ured innate antiviral factors in Nicaraguan mothers' milk and immune response to the first dose of the pentavalent rotavirus vaccine 
in corresponding infants. No relationship was found between concentrations of innate factors and rotavirus vaccine response.
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Although the greatest burden of rotavirus disease is in LMICs, 
oral rotavirus vaccines (RVs) have lower efficacy in these set-
tings [1–3]. In Nicaragua, the pentavalent RV (RV5) provides 
approximately 46% effectiveness against hospitalization for 
rotavirus diarrhea, compared with estimates of 82% to 95% 
in the United States [4, 5]. One possible explanation for lower 
effectiveness in LMIC infants is direct inhibition of this oral 
vaccine by acquired or innate immune factors present in breast 
milk. Breast milk inhibits RVs in vitro, activity that could be 
mediated by innate antimicrobial proteins. The innate factor 
lactoferrin is present in breast milk, and it inhibits rotavirus 
activity [6]. Another innate factor in breast milk, lactadherin, 
is associated with protection against symptomatic rotavirus 
infection [7]. Tenascin-C (TNC) is an innate, highly charged, 
hexameric protein present in breast milk that inhibits human 
immunodeficiency virus replication via interruption of virus-
host receptor interactions [8], and it may also be important in 
the inhibition of other viral pathogens. These innate factors, 
together with acquired immunity in breast milk, could reduce 
virus replication in the infant gastrointestinal tract and blunt 
the infant's response to RVs. Furthermore, breast milk from 
LMIC mothers has higher concentrations of (1) lactoferrin and 
lactadherin and (2) rotavirus-specific immunoglobulin (Ig)A 
titers compared with mothers from high-income countries [9, 
10], indicating a greater potential for RV inhibition. To address 
this concern, clinical trials of transient breastfeeding withhold-
ing have been conducted at the time of RV administration [11, 
12]; in these trials, breastfeeding withholding for a total of 2 
hours did not improve the infant's immune response to RVs.
We have previously shown that high titers of rotavirus-spe-
cific IgG antibody in maternal serum are associated with fail-
ure to seroconvert to RV5 in corresponding infants, whereas 
rotavirus-specific IgA titers in breast milk were not associated 
with seroconversion [13]. The objective of this study was to test 
whether there is an association between innate factors in breast 
milk and infants' RV-elicited immune responses. We examined 
the association between levels of lactoferrin, lactadherin, and 
TNC in breast milk, breast milk neutralization of RV5, and 
immunogenicity to the first dose of RV5 in respective infants. 
We hypothesized that high concentrations of innate factors in 
breast milk would be associated with decreased RV-elicited 
immune responses.
METHODS
Study Setting and Design
This study was performed in León, Nicaragua. At the time of 
the study, the national immunization schedule included RV5 at 
2, 4, and 6 months of age. Mother-infant pairs were recruited 
in their households in September and October 2012, using 
public health rosters of pregnancies and live births in the Perla 
Maria and Subtaiva Health Sectors of León [13]. The recruit-
ment visit occurred 1  day before the infant's first immuniza-
tion visit. Eligibility criteria for infants included gestational 
age greater than 35 weeks at birth, birthweight of 2.5–4.5  kg, 
no known chronic health conditions, currently breastfeed-
ing at least 4 times daily, eligible to receive RV5, and mother 
without known immune disorder or blood transfusion within 
© The Author 2015. Published by Oxford University Press on behalf of the Pediatric Infectious 
Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
DOI: 10.1093/jpids/piv076
Received 11 June 2015; accepted 13 October 2015.
Correspondence: S. Becker-Dreps, MD, MPH, UNC Department of Family Medicine, 590 
Manning Drive, Chapel Hill, NC 27599-7595. E-mail: sbd@unc.edu.
88 • JPIDS 2017:6 (March) • Becker-Dreps et al
the past 9 months. Informed consent was obtained from each 
mother for involvement of the mother-infant pair. The study 
was approved by institutional review boards of the Universidad 
Nacional Autónoma de Nicaragua, León and the University of 
North Carolina at Chapel Hill.
At recruitment, a preimmunization serum sample was 
obtained from each infant. At the same visit, breast milk and 
serum samples were obtained from each mother. The following 
day, infants received RV5 according to the national immuniza-
tion schedule in the public health facility. A study nurse who 
accompanied each of the pairs to the infant's first immuniza-
tion visit recorded breastfeeding patterns by direct observation. 
Four weeks after the first dose of RV5, a second serum sample 
was obtained from each infant in the household.
LABORATORY METHODS
Samples were transported at 4°C to the University Microbiology 
Laboratory where serum samples were separated and then 
stored at −70°C and breast milk samples were stored at −70°C. 
Commercial kits were used to assay breast milk concentrations 
of lactoferrin (Innovative Research Inc, Novi, MI) and lact-
adherin (Boster Bio, Pleasanton, CA). TNC concentrations in 
breast milk were determined by enzyme-linked immunosorbent 
assay (ELISA). In serially diluted samples, TNC was detected 
with mouse anti-TNC monoclonal antibody (Fisher Scientific) 
and antimouse peroxidase-conjugated antibody (Promega). 
Tetramethylbenzidine substrate was added and absorbance read 
at 450 nm. TNC concentration was determined by comparison 
to dilutions of quantitated purified TNC protein (Millipore, 
Billerica, MA), with detection limit of 4.88 ng/mL. Rotavirus-
specific IgA titers in milk were assayed by enzyme immunoas-
say, and neutralizing antibody titers in milk were assayed using 
a microneutralization assay, both as previously described [9]. 
Serum rotavirus-specific IgA was assayed by ELISA [9, 14].
Statistical Analysis
Seroconversion to the first RV5 dose was defined as a 4-fold 
or greater increase in rotavirus-specific IgA titers in the infant's 
postimmunization serum sample compared with the preim-
munization sample.Spearman's rank correlation coefficients 
(ρ) were estimated to examine correlations between concentra-
tions of innate factors, between innate factors and breast milk 
antibody titers, and between innate factors and fold change in 
infant rotavirus-specific IgA titers before and after immuniza-
tion. Wilcoxon rank-sum tests were used to compare concen-
trations of innate factors between infants who did versus did 
not seroconvert to RV5.
To evaluate the association between the combined effect 
of innate factors and seroconversion, 2 composite scores were 
developed. The “innate factor” score, of 0 to 3, was generated by 
adding 3 points for each innate factor concentration (lactoferrin, 
lactadherin, and TNC) in the highest quartile, 2 points for each 
innate factor concentration in the second highest quartile, and 
1 point for each innate factor concentration in the third highest 
quartile (no points were assigned for innate factor concentrations 
in the lowest quartile), and then dividing this sum by 3 to generate 
a mean. The “innate and acquired immunity” score, of 0 to 6, is 
a composite score in which innate immunity contributes 50% of 
the score and acquired immunity (breast milk rotavirus-specific 
IgA titer) contributes the remaining 50% of the score. This score 
equals the innate factor score (as stated above) summed with 3 
points for a breast milk IgA titer in the highest quartile, 2 points 
for an IgA titer in the second highest quartile, or 1 point for an 
IgA titer in the third highest quartile. Two-sided exact Wilcoxon 
rank-sum tests were used to compare these scores between 
infants who did versus did not seroconvert to RV5.
RESULTS
Of the 49 mother-infant pairs enrolled, 45 completed study 
requirements, including 2 infant blood draws and receipt of 
RV5 by the infant. The 45 infants were 47% male, had a median 
birthweight of 3200 grams, and had a median age of 2 months of 
age upon study entry and 3 months of age at the time of the sec-
ond serum collection. Fifty-three percent lived in the primarily 
urban region of Perla Maria and 47% lived in Subtiava, which 
included both urban and periurban regions. Mother-infant 
pairs lived in households with the following characteristics: 
96% had municipal piped water, 71% had an indoor toilet, and 
80% had nondirt floors. Infants in the study breastfed a median 
number of 10 times per day; 29% were exclusively breastfed. 
Breastfeeding was observed at the immunization visit, on aver-
age, within 8 minutes before or after receipt of RV5 (range, 0–43 
minutes).
Sixty-nine percent (31 of 45)  of infants met the serocon-
version definition after the first dose of RV5. Breast milk from 
mothers had a median lactoferrin concentration of 811.4 µg/mL 
(interquartile range [IQR], 669.2–1404.2), a median lactadherin 
concentration of 5.4 µg/mL (IQR, 4.0–7.3), a median TNC con-
centration of 9.7 µg/mL (IQR, 4.9–16.4), and, as reported pre-
viously [13], median rotavirus-specific IgA titers of 160 (IQR, 
160–320), and median rotavirus-specific neutralizing antibody 
titers of 1 (IQR, 1–4).
Lactoferrin concentration in breast milk was moderately cor-
related with neutralizing antibody titer and rotavirus-specific 
IgA titer in breast milk (ρ = 0.66 and ρ = 0.54, respectively; P < 
.001). Lactadherin concentration in breast milk was moderately 
correlated with breast milk neutralizing antibody titer (ρ = 0.42; 
P < .001), but it did not show evidence of correlation with breast 
milk rotavirus-specific IgA titers (P = .25). TNC concentration 
in breast milk was moderately correlated with breast milk rota-
virus-specific IgA titer (ρ = 0.34; P = .02), but it did not show 
evidence of correlation with breast milk neutralizing antibody 
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titer (P = .18). Concentrations of the innate factors were mod-
erately correlated with each other (lactoferrin and lactadherin, 
ρ = 0.62; lactoferrin and TNC, ρ = 0.46; lactadherin and TNC, 
ρ = 0.45 [P < .001]).
When examined individually, there were no statistically sig-
nificant differences in concentrations of breast milk lactofer-
rin, lactadherin, or TNC concentrations between the groups of 
infants who did vs did not seroconvert to the first dose of RV5 
(Table 1). There were also no statistically significant differences 
between the innate factor score or innate and acquired immu-
nity score of breast milk between the groups of infants who did 
versus did not seroconvert to RV5 (Table 1). Furthermore, there 
was no correlation between either score and fold-change in 
infant rotavirus-specific IgA titer.
DISCUSSION
Oral vaccines provided to breastfed infants could potentially be 
inhibited by immune factors in breast milk, a concern raised 
by in vitro and postlicensure studies [9, 10]. In a prior study, 
we did not find a clear association between acquired immunity 
in breast milk and RV5 seroconversion in infants [13]. In this 
study, we further examined the relationship between innate 
antiviral factors in breast milk and infant RV5 seroconversion, 
both individually and as combined scores. Although we did find 
an association between (1) the concentrations of lactoferrin and 
lactadherin and (2) breast milk neutralization of rotavirus, we 
did not find a relationship between concentrations of these 
innate antiviral factors in breast milk and infant seroconver-
sion to the first dose of RV5. Of note, this was the first study to 
combine concentrations of innate factors into scores to examine 
their combined effect. In contrast with the lack of association 
of breast milk immunity with seroconversion, as we reported 
previously, high maternal serum humoral immunity appears to 
most strongly predict failure to seroconvert to RV5 [13], sug-
gesting potential interference by placentally transferred mater-
nal IgG with infant response to RV5.
However, we did find that the concentrations of each of these 
innate factors in breast milk were moderately correlated to each 
other, suggesting that the concentration of these proteins is pre-
dicted by total milk protein content. In addition, as lactoferrin 
and lactadherin concentrations were moderately correlated 
with neutralizing antibody titers in breast milk, this suggests 
that they may serve a role in protecting the infant against natu-
ral rotavirus infection.
Although this study was limited by a small sample size, our 
findings do not support the withholding of breastfeeding at the 
time of RV administration as a potential intervention to improve 
infant RV response. Two prior studies have examined the effect 
of breastfeeding withholding at the time of RV administration, 
and neither found a benefit in terms of improved immunoge-
nicity [11, 12].
CONCLUSIONS
In conclusion, this preliminary study found that innate antiviral 
factors in breast milk are not associated with RV5 seroconver-
sion in infants. Future research should focus on maternal IgG 
antibody interference and other host factors in LMIC infants to 
better understand and develop strategies to improve the effec-
tiveness of RVs in these settings.
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